December 1, 2021 -- Northwest Biotherapeutics, a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, has secured $15 million in financing to accelerate its brain cancer program.
The financing is in the form of a 22-month loan which requires no payments for eight months followed by a 14-month amortization period.
Northwest is developing platform technology for its DCVax dendritic cell-based vaccines. These personalized immunotherapy products are designed to treat cancers without the toxicities that are associated with chemotherapies. DCVaxI has completed a 40-patient phase I trial for inoperable solid tumors, and the company is planning to pursue a phase II trial next.
Copyright © 2021 scienceboard.net